--- title: "Hot pre-market trades in US stocks: Genprex up 15.86% pre-market; Keysight Tech up 14.70% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/276708334.md" description: "Genprex pre-market up 15.86%; Keysight Tech pre-market up 14.70%; Vir Biotechnology pre-market up 50.47%; Blue Hat pre-market up 37.99%; Silo Pharma pre-market up 31.93%" datetime: "2026-02-24T09:07:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276708334.md) - [en](https://longbridge.com/en/news/276708334.md) - [zh-HK](https://longbridge.com/zh-HK/news/276708334.md) --- # Hot pre-market trades in US stocks: Genprex up 15.86% pre-market; Keysight Tech up 14.70% pre-market **Pre-market Hot Trades in US Stocks** Genprex is up 15.86% in pre-market trading. Based on recent key news: 1. On February 23, Genprex announced that the Japan Patent Office made a favorable appeal decision, granting a patent related to the combination of Reqorsa gene therapy and PD-L1 antibodies for cancer treatment. This news drove the stock price up. 2. On February 23, Genprex also stated that the European Patent Office decided to grant a patent related to the combination of Reqorsa and PD-1 antibodies for cancer treatment. This further enhanced market confidence in the company's future development. 3. No other significant news recently. Competition in the gene therapy field is intensifying, and risks should be monitored. Keysight Tech is up 14.70% in pre-market trading. Based on recent key news: 1. On February 23, Keysight Tech's earnings report showed that its first fiscal quarter performance exceeded analyst expectations, with revenue reaching $1.6 billion, a year-on-year increase of 23%, and diluted earnings per share of $2.17, all above market expectations. This performance drove the stock price up 14.80% in after-hours trading. Source: IT Home 2. On February 23, JP Morgan raised Keysight Tech's target stock price from $255 to $300, reflecting market confidence in its future growth. Source: Benzinga 3. On February 23, Keysight Tech projected that its second fiscal quarter revenue would reach $1.6±0.1 billion, a year-on-year increase of about 30%, with diluted earnings per share expected to be $2.30±0.03, significantly higher than the average analyst estimate. This optimistic earnings outlook further boosted investor confidence. Source: IT Home The semiconductor industry is experiencing strong demand, with increased AI investment. **Top Gainers in Pre-market US Stocks** Vir Biotechnology is up 50.47% in pre-market trading. Based on recent key news: 1. On February 24, Vir Biotechnology reached a collaboration agreement with Astellas Pharma to develop and commercialize VIR-5500 for the treatment of prostate cancer. The agreement includes a $335 million upfront payment and recent milestone payments, as well as up to $1.37 billion in development, regulatory, and sales milestone payments. This news drove the stock price up about 55%. Source: Reuters 2. On February 24, Vir Biotechnology reported fourth-quarter sales performance that exceeded expectations, with revenue reaching $64.07 million, a year-on-year increase of 417.9%. This performance enhanced market confidence, and the stock price rose 65%. Source: Reuters 3. On February 23, Vir Biotechnology released positive Phase I trial results for VIR-5500, showing dose-dependent anti-tumor activity, which drove the stock price up. Source: Reuters The biotechnology industry faces regulatory risks, and stock price volatility is high Blue Hat pre-market rose 37.99%. Based on recent key news: 4. On February 21, Blue Hat announced it would raise funds by issuing an additional 4.8 million units to support its strategic shift from augmented reality gaming to global commodity trading. This move may lead to equity dilution but provides the necessary financial support for the company. According to Benzinga, the stock fell over 70% on Friday, hitting a new 52-week low. 5. On February 23, Blue Hat expects to complete the issuance on the same day, with the proceeds to be used for working capital and general corporate purposes. This transformation strategy may boost market expectations for its future growth, leading to a pre-market rise in stock price. 6. No other significant news recently. The transformation in the commodity trading industry has drawn attention. Silo Pharma pre-market rose 31.93%. Based on recent key news: 1. On February 23, Silo Pharma announced a $1 million stock repurchase plan. This move indicates that management believes the current market conditions undervalue the company's stock and aims to enhance shareholder value. Following this announcement, the stock price rose significantly. Source: Reuters 2. On February 23, Silo Pharma's trading volume increased, showing a positive market response to the repurchase plan. The company previously reported 13.3 million shares outstanding as of November 13, 2025. Source: Reuters 3. On February 23, Silo Pharma released relevant information through the EDGAR system, further confirming the details of the repurchase plan. This move boosted investor confidence and drove the stock price up. The biopharmaceutical industry has been active recently, with significant capital inflows ### Related Stocks - [GNPX.US](https://longbridge.com/en/quote/GNPX.US.md) - [KEYS.US](https://longbridge.com/en/quote/KEYS.US.md) ## Related News & Research - [Keysight and SRC UK Collaborate to Advance EW Modernization with Advanced Test and Simulation | KEYS Stock News](https://longbridge.com/en/news/286436302.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md) - [What To Expect From Keysight’s (KEYS) Q1 Earnings](https://longbridge.com/en/news/286706596.md) - [These Analysts Increase Their Forecasts On Keysight After Strong Q2 Results](https://longbridge.com/en/news/287086019.md) - [Keysight Technologies (KEYS) to Release Quarterly Earnings on Tuesday](https://longbridge.com/en/news/286078380.md)